BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its fourth-quarter and full-year 2022 financial results on Wednesday, March 1, 2023, prior to the open of U.S. financial markets.

Masimo (NASDAQ: MASI) today announced the limited market release of Visual Clinical Activity Monitoring (VCAM™), a video analysis system that uses artificial intelligence to help facilitate compliance with hospital hand hygiene protocols.

Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure.

Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of John Hamill as Chief Financial Officer.

CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously announced underwritten public offering of its common stock and pre-funded warrants.

Genetic Technologies Limited, a global leader in guidance-driven genomics-based tests in health, wellness and serious diseases releases its Quarterly business update for the quarter ended 31 December 2022.

Halia Therapeutics today announced that David J. Bearss , Ph.D., CEO of Halia Therapeutics, will be presenting at the BIO CEO & Investor Conference on Tuesday, February 7.

Vaccitech plc today announced the appointment of Nadège Pelletier, Ph.D., as Chief Scientific Officer (CSO).

Kintara Therapeutics, Inc. today announced that Robert E. Hoffman , President and CEO of Kintara, will be presenting at the BIO CEO & Investor Conference on Monday, February 6, 2023.